Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Core Insights - Revolution Medicines, Inc. is set to present 11 oral and poster presentations at the AACR Annual Meeting in Chicago from April 25 – 30, 2025, focusing on targeted therapies for RAS-addicted cancers [1][7]. Oral Presentations - The first clinical data from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be presented in a late-breaking oral session on April 27, 2025 [2]. - The presentations include topics such as the preliminary safety and antitumor activity of zoldonrasib in KRAS G12D non-small cell lung cancer, and the discovery of RMC-5127, a RAS(ON) G12V-selective inhibitor [2]. Poster Presentations - Key poster presentations will cover early reductions in circulating tumor DNA (ctDNA) associated with clinical activity of daraxonrasib in RAS mutant non-small cell lung cancer, and mechanisms of resistance to daraxonrasib [3][4]. - Additional topics include the combination of RAS(ON) inhibitors to enhance immunotherapy efficacy in RAS-driven preclinical models [3]. Collaborator Presentations - Collaborator presentations will discuss distinct regulation of Cyclin D in colorectal cancer models and overcoming resistance to sotorasib through combination therapies [5][6]. - Other presentations will focus on long-term tumor control through combination therapy and preclinical evaluations of RMC-7977 for KRAS-mutant cholangiocarcinoma [5][6]. Company Overview - Revolution Medicines is a late-stage clinical oncology company developing targeted therapies for RAS-addicted cancers, with a pipeline that includes daraxonrasib, elironrasib, and zoldonrasib currently in clinical development [7]. - The company is also advancing RMC-5127, a RAS(ON) G12V-selective inhibitor, and exploring additional RAS(ON) mutant-selective inhibitors [7].